Tesfamariam B, Allen G T, Powell J R
Department of Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA.
Eur J Pharmacol. 1995 Jul 25;281(1):17-20. doi: 10.1016/0014-2999(95)00218-a.
The present study was undertaken to characterize the direct chronotropic effect of bradykinin in isolated spontaneously beating atria of the guinea pig. Bradykinin caused concentration-dependent increases in the beating rate of atria. In contrast, the active metabolite of bradykinin and the typical bradykinin B1 receptor agonist, Des-Arg9-bradykinin, had no effect on the beating rate of atria. Inhibition of converting enzyme or neutral endopeptidase by captopril or SQ-28603, respectively, did not affect beating rate but potentiated bradykinin-induced increase in beating rate. The potent bradykinin B2 receptor antagonist, HOE 140, antagonized bradykinin-induced chronotropic effect. In contrast, the bradykinin B1 receptor antagonist, Lys-[Leu8]Des-Arg9-bradykinin, had no effect. The increase in beating rate caused by bradykinin was not affected by blockade of beta 1-adrenoceptors, cyclooxygenase, or nitric oxide synthesis using atenolol, indomethacin and N omega-nitro-L-arginine, respectively. Unlike bradykinin, angiotensin I and angiotensin II caused very small or no change in beating rate in the presence or absence of captopril and SQ-28603. These results indicate that bradykinin causes a direct positive chronotropic effect which is mediated by activation of bradykinin B2 receptors independently of prostaglandins and beta 1-adrenoceptors.
本研究旨在描述缓激肽对豚鼠离体自发搏动心房的直接变时作用。缓激肽可使心房搏动频率呈浓度依赖性增加。相比之下,缓激肽的活性代谢产物以及典型的缓激肽B1受体激动剂去-精氨酸9-缓激肽对心房搏动频率无影响。分别用卡托普利或SQ-28603抑制转化酶或中性内肽酶,对搏动频率无影响,但可增强缓激肽诱导的搏动频率增加。强效的缓激肽B2受体拮抗剂HOE 140可拮抗缓激肽诱导的变时作用。相比之下,缓激肽B1受体拮抗剂赖氨酸-[亮氨酸8]去-精氨酸9-缓激肽则无作用。分别使用阿替洛尔、吲哚美辛和Nω-硝基-L-精氨酸阻断β1肾上腺素能受体、环氧化酶或一氧化氮合成,对缓激肽引起的搏动频率增加无影响。与缓激肽不同,在存在或不存在卡托普利和SQ-28603的情况下,血管紧张素I和血管紧张素II引起的搏动频率变化非常小或无变化。这些结果表明,缓激肽可产生直接的正性变时作用,该作用由缓激肽B2受体激活介导,且独立于前列腺素和β1肾上腺素能受体。